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ABSTRACT
Introduction: In the USA, nearly one in three
people will experience herpes zoster (HZ) in
their lifetime. Underserved communities may
be at even higher risk due to several factors,
including access to healthcare, education, and
co-morbid conditions. The purpose of this study
was to investigate current knowledge, attitudes,
beliefs and practices (KABP) relative to HZ and
HZ vaccines in a large urban city.
Methods: A cross-sectional KABP survey was
conducted via in-person interview among 381
participants aged C 50 years in Detroit, MI,
USA, from June to August 2018. Survey results
were stratified into two groups [\60
and C 60 years of age (YO)] for comparison.
Results: Of the 381 participants, 373 reported
their age (110\60 YO and 263 C 60 YO).
Overall, the majority of participants reported
having heard of HZ and HZ vaccines. In addi-
tion, receiving a recommendation from a
healthcare provider (37.5%) followed by gain-
ing a better understanding of HZ vaccine
(36.7%) and of HZ (29.9%) were leading factors
that influenced participants’ willingness to
receive the vaccine. Of note, 65.5% of partici-
pants\60 YO reported the belief that HZ is
preventable versus only 53.2% in those C 60
YO (p = 0.001).
Conclusion: Our findings underscore the need
to educate patients in underserved communi-
ties about HZ as well as new HZ vaccine rec-
ommendations to improve vaccination rates
and reduce the incidence of HZ and its associ-
ated sequelae.
Keywords: Herpes zoster; Shingles; Survey;
Vaccination
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INTRODUCTION
Herpes zoster (HZ), or shingles, results from
reactivation of the varicella-zoster virus. It is
estimated that one out of every three people in
the USA will develop HZ during their lifetime,
and 13% of people C 60 years of age will
develop post-herpetic neuralgia (PHN), which
can significantly reduce quality of life [1].
Despite the recognized burden of HZ and PHN,
HZ vaccination rates in the US remain low.
Whites have significantly higher HZ vaccina-
tion rates (37.7%) compared with Asians
(21.9%), Hispanics (21.4%) and African Ameri-
cans (15.7%) [2]. Additional factors such as
education, household income and existing
relationship with a healthcare provider have
been independently associated with HZ vacci-
nation [3]. Such disparities in HZ immunization
rates may reflect the interrelationship of health
and socioeconomic disparities between these
racial/ethnic groups found across the US [4].
In October 2017, the US Food and Drug
Administration approved a new recombinant
zoster vaccine, Shingrix (GlaxoSmithKline,
Rixensart, Belgium). Evidence shows the effi-
cacy of Shingrix against HZ at 97%, a sub-
stantial improvement from 51% displayed by
the live zoster vaccine, Zostavax (Merck & Co.,
Inc., Whitehouse Station, NJ, USA), the only HZ
vaccine available in the US prior the approval of
Shingrix [5, 6]. Increasing patient uptake of
this new and more effective vaccine has poten-
tial to significantly reduce HZ disease burden.
Thus, it is important to gauge patient under-
standing of HZ and HZ vaccines, particularly in
disadvantaged populations that suffer from
health disparities. In this report, we assess
knowledge, attitudes, beliefs and practices
(KABP) among people residing in a large urban
American city with a high proportion of medi-
cally underserved individuals and families to
identify potential opportunities to improve HZ
awareness and vaccine uptake.
METHODS
Study Overview
A KABP survey was developed, and convenience
sampling was conducted at four different loca-
tions (two large retail stores located in the city’s
suburban neighborhoods and two community
centers located in combined commercial/resi-
dential districts) in Detroit, MI, USA. This city
was chosen because it houses the institution
conducting the study and is demographically
characteristic of an underserved area with sig-
nificant healthcare disparities. According to the
US Health Resources & Services Administration,
Detroit is a federally designated health profes-
sional shortage area for primary care, and nearly
every square mile of the city is designated as a
medically underserved area [7]. The city’s pop-
ulation is just over 670,000 residents, 79.1% of
whom are Black or African American, 9.9%
White and 7.6% Hispanic or Latinx [8]. In
addition, the median household income in
Detroit in 2017 was $27,838, and 37.9% of its
residents live in poverty [8].
Participants were recruited via flyers and/or
approached in person by study personnel, and
verbal agreement to participate in the survey
was obtained. All participants received a study
information sheet. Upon verbal consent and
confirmation that their age was C 50 years by
study personnel (participants asked: ‘‘are you
50 years or older?’’ and this question was
included in the demographic section of the
survey), study personnel then performed a face-
to-face interview using a paper-based survey
instrument. After completing the survey, par-
ticipants received HZ-based educational hand-
outs and a $10.00 gift card to a local retailer.
People who had never heard of shingles were
excluded from this study. The Wayne State
University Institutional Review Board reviewed
and approved this study (reference no.
043918B3X). This study conformed with the
Helsinki Declaration of 1964, as revised in 2013,
concerning human and animal rights, and
Springer’s policy concerning informed consent
has been followed.
688 Infect Dis Ther (2019) 8:687–694
Survey Instrument
The survey is available in the supplementary
material and consisted of 42 multiple-choice
items. It consisted of five sections: demo-
graphic, knowledge (20 items), attitudes (11
items), beliefs and influence of practice toward
HZ vaccines (11 items). HZ was referred to as
‘shingles’ in the survey. Participants were
instructed to completely answer each item
based on their current knowledge.
Data Collection and Statistical Analysis
Sample size estimation assumed a statistical
power of 0.8 and a confidence level of 95%
(alpha = 0.05). Assuming a target population of
209,409 aged C 50 years in Detroit, and an
overall response rate of at least 80%, we esti-
mated a required sample size of 350 individuals.
Surveys were administered by trained key per-
sonnel from June to August 2018. Answers from
paper-based surveys were transcribed into the
Research Electronic Data Capture (REDCap) tool
(est. 2004 Vanderbilt University, Nashville, TN)
and analyzed using SPSS (ver. 24) statistical
analysis software (2016; IBM Corp. Armonk,
NY). Univariate (chi-square or Fisher’s exact
test) analyses were used to describe patterns of




Three hundred eighty-one participants com-
pleted the survey, and of these 373 provided
information on age. Sixty-five percent (n = 241)
of participants were female, and 90.3%
(n = 344) were Black or African American. Par-
ticipants were stratified into two groups [age\
60 or C 60 years old (YO); Fig. 1]. This age cut-
off was chosen to allow for better understand-
ing of zoster knowledge, behaviors and
practices among those at lower or greater risk
for HZ [1].
Knowledge of HZ and HZ Vaccines
When asked ‘‘do you think that shingles is
common in the US,’’ the majority of both
groups (\60 YO and C 60 YO) chose ‘‘yes’’
(69.1% and 68.5%). The majority also reported
knowing at least one person who had HZ in the
past (68.2% and 68.4%); 13.3% of partici-
pants C 60 YO had reported experiencing HZ
personally compared with only 8.2% of partic-
ipants\60 YO. The majority of both groups
knew that HZ is a nerve/skin disease (96.4% and
93.1%), and that adults aged C 50 years had a
higher risk of HZ (69.1% and 66.9%) than those
\ 50 years. Participants of both age groups
selected post-herpetic neuralgia (PHN) as the
most common complication of HZ (40.4% and
44.4%) followed by rash (39.7% and 33.2%).
Participants of both age groups knew that HZ
can be recurrent (61.8% and 58.6%) and that HZ
is not transmitted person to person (49.1% and
56.3%).
Most participants of both groups (\60 YO
and C 60 YO) had heard of the HZ vaccine
(Fig. 2). The most common information source
for hearing about the HZ vaccine was television
or internet advertisements (36.0% and 37.2%)
followed by their doctor (25.2% and 31.4%) and
their pharmacist (9.7% and 14.2%). Interest-
ingly, a significantly higher proportion of
respondents\60 YO (62.7%) felt that the HZ
vaccine was associated with side effects versus
those C 60 YO (39.2%; p\0.001), and 35%
(29.1% in\60 YO and 36.9% in C 60 YO) of
overall participants did not know that the HZ
vaccine was associated with any side effects.
Attitudes and Beliefs Toward HZ and HZ
Vaccines
Most participants of both groups believed that
HZ can be treated (92.7% and 93.9%). Of those,
67.6% of participants\60 YO thought treat-
ments were safe and effective compared with
71.3% of participants C 60 YO. Over half of
participants of both groups thought HZ is cur-
able (60.0% and 63.1%). However, only 53.2%
of participants C 60 YO thought HZ is pre-
ventable compared with 65.5% of
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participants\60 YO (p = 0.001). About 18% of
both groups thought that it was very unlikely
that they could experience shingles while only
12% thought they were very likely to get shin-
gles, now or in the future. Most participants
thought that the pain associated with HZ is
serious (67.3% and 60.5%).
In questions related to vaccine safety and
efficacy, [ 50% of participants of both groups
believed that HZ vaccines were safe and effec-
tive. Additional survey data related to attitudes
and beliefs are shown in Fig. 3.
Practices Toward HZ and HZ Vaccines
Only 19.1% of participants\ 60 YO indicated
that they received a recommendation for a
shingles vaccine from their healthcare provider
versus 43.3% of participants C 60 YO
(p = 0.000) (Table 1). Willingness to receive the
shingles vaccine was reported among 46.4% of
participants\60 YO compared with 50.2% in
participants C 60 YO (p = 0.750). In addition, a
high proportion of participants in both the
younger and older age groups expressed a will-
















Female (n=241) Male (n=132) Black or African
American
(n=344)
White (n=21) Others (n=8)
<60 years (a) ≥60 years (b)
Sex (P-value = 0.228) Race (P-value = 0.07546)
Fig. 1 Demographic characteristics of participants (%) by age group. aMean (standard deviation): 54.4 (3.1) years. Range



























<60 years ≥60 years <60 years ≥60 years <60 years ≥60 years
Have you heard of the shingles vaccine?
(P-value = 0.457)
Do you know anyone that has received
the shingles vaccine? (P-value = 0.299)
Do you think the shingles (Herpes Zoster)
vaccine has any side effects? (P-value =
0.000)
Yes No Don't Know
Fig. 2 Knowledge of herpes zoster vaccines
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healthcare provider about the shingles vaccine
(84.5% in\ 60 YO vs. 87.1% in C 60 YO).
We asked both age groups whether they
would be willing to receive the vaccine based on
a recommendation from three different
healthcare professionals: a doctor, a nurse and a
pharmacist; 71.8% of participants\60 YO and
73.0% of those C 60 YO stated they would
based on a doctor’s recommendation followed
by recommendation from a nurse (53.6% and
54.0%) and, lastly, a recommendation from a





























<60 years ≥60 years <60 years ≥60 years <60 years ≥60 years
Do you think shingles can be prevented?
(P-value = 0.001)
Do you think that shingles can cause
death? (P-value = 0.431)
Do you think the shingles vaccine can
cause shingles? (P-value = 0.069)
Yes No Don't Know
Fig. 3 Attitudes and beliefs regarding shingles and shingles vaccines
Table 1 Practices toward herpes zoster and herpes zoster vaccines





Did your doctor/pharmacist or other healthcare provider ever recommend you to
be vaccinated with the shingles vaccine?
Yes 135 21 (19.1) 114 (43.3) 0.000
No 238 89 (80.9) 149 (56.7)
All other things being equal, if you are offered a shingles vaccine that is 97.2%
protective and requires two doses gives 2 months apart (vaccine #1) or a shingles
vaccine that is 51.3% protective and requires one dose (vaccine #2), which
vaccine would you choose?
Vaccine #1 313 97 (88.2) 216 (82.1) 0.200
Vaccine #2 52 10 (9.1) 42 (16.0)
Others 8 3 (2.7) 5 (1.9)
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significant differences were found in willingness
to take healthcare provider recommendations
when comparing the two age groups.
When given the choice between ‘‘vaccine #1
(97.2% protective, requiring two doses
2 months apart) vs. vaccine #2 (51.3% protec-
tive, requiring one dose),’’ 88.2% of respon-
dents\60 YO selected vaccine #1 compared
with 82.1% of respondents C 60 YO (p = 0.200).
Regarding vaccine cost, 31.4% of partici-
pants reported willingness to receive the vac-
cine only if it were provided free of charge.
Thirty-six percent of participants were willing
to pay up to $24.99 USD, and 18.7% were will-
ing to pay $25.00 to 50.00 USD. One-hundred
forty-three (37.5%) participants reported that a
recommendation by a healthcare provider was
the most important factor that would change
their decision to receive the vaccine followed by
gaining a better understanding of the vaccine
(36.7%), gaining a better understanding of the
disease (29.9%), reduced cost of the vaccine
(11.8%) and ‘‘other’’ factor(s) (3.7%).
DISCUSSION
In a representative sample of medically under-
served and socioeconomically challenged par-
ticipants, knowledge, attitudes, beliefs and
practices regarding HZ and HZ vaccines were
highly variable. These findings are consistent
with existing studies, including those in char-
acteristically different populations [9–11].
Our results demonstrate that provider rec-
ommendations play a vital role in promoting
HZ vaccination by positively influencing will-
ingness to receive the vaccine. This concept has
been displayed in a similar study by Teeter et al.,
which found that among 681 participants, there
was over a fivefold increase in likelihood of
vaccination if they received a recommendation
from a healthcare provider [12]. It should be
noted however that the majority of participants
in this study were white and unvaccinated. Our
study provides a unique perspective, as it is the
only survey on HZ and HZ vaccines, to our
knowledge, that was conducted in an under-
served, urban environment with a socioeco-
nomically challenged population.
Despite the importance of provider recom-
mendations, only 36.1% of survey respondents
reported receiving a recommendation for the
shingles vaccine from their healthcare provider,
representing a significant missed opportunity to
more frequently and effectively educate eligible
patients [13]. Furthermore, despite a lower rec-
ommendation acceptance rate compared with
doctors and nurses, pharmacists’ ability to pro-
vide vaccinations and their increased accessi-
bility compared with other healthcare providers
represent another opportunity for patient edu-
cation. Efforts that provide training to phar-
macists in vaccine communication with
patients and caregivers may help reduce missed
vaccination opportunities at the pharmacy
level.
In the US and other countries, the high cost
of the HZ vaccine is a well-established barrier to
vaccination [14]. However, results of our study
revealed that reducing the cost of the HZ vac-
cine was only the fourth most important factor
that would change participants’ decision to
receive the vaccine, when given the choice of
the following factors: recommendation by a
healthcare provider, gaining a better under-
standing of the HZ vaccine, gaining a better
understanding of HZ, reduced cost of the vac-
cine and ‘other.’ These data suggest that vaccine
cost is not the sole reason for the inability to
receive HZ vaccination among patients in
medically underserved communities. Other
reasons for not receiving HZ vaccination
include important factors such as having ade-
quate insurance coverage and access to
transportation.
The efficacy of existing vaccines against HZ
and the number of doses required were found to
be other important factors in willingness to
receive vaccinations. Given efficacy rates and
dose series requirements of the two HZ vaccines
currently utilized, the vast majority of partici-
pants stated they would choose the option with
a higher efficacy rate, even if it required two
doses instead of just one. This shows that pro-
viding patients basic evidentiary information
on vaccines can be a major tool to overcome the
barrier of multiple-dose requirements, even in
the medically underserved.
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A few limitations apply to our study. First,
our survey was investigator-created and non-
validated. Survey responses were self-reported
and are thus susceptible to recall bias. In addi-
tion, although the survey was conducted in a
medically underserved demographic, we were
unable to verify the educational background
and/or socioeconomic status of each partici-
pant, as this information was not collected.
Lastly, because this survey was conducted in a
primarily African American population, the
results may be less representative of other pop-
ulations with a predominance of other racial/
ethnic groups.
CONCLUSION
Our findings contribute to understanding the
KABPs regarding HZ and HZ vaccines in a sam-
ple of primarily African American persons in a
medically underserved, socioeconomically
challenged community. Our study suggests that
lack of vaccine recommendations from health-
care providers may be a significant factor influ-
encing low HZ vaccination rates in these
communities. It is crucial to educate patients
about HZ and its complications, as well as basic
information regarding HZ vaccines, to improve
vaccination rates and reduce the incidence of
HZ. Future research should focus on continued
identification of barriers to vaccination through
KABP assessment in diverse populations and
training all types of HCPs to improve the
delivery and increase the frequency of recom-
mendations for HZ vaccination to their
patients.
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